Видео ютуба по тегу Azacitidine

Azacitidine treatment toxicities
Azacitidine treatment toxicities
Treatment benefits for elderly AML patients with azacitidine
Treatment benefits for elderly AML patients with azacitidine
Phase I trial results for oral azacitidine and venetoclax in R/R AML
Phase I trial results for oral azacitidine and venetoclax in R/R AML
Establishing the clinical benchmark of azacitidine in patients with MDS
Establishing the clinical benchmark of azacitidine in patients with MDS
Venetoclax and azacitidine for AML ineligible for standard induction
Venetoclax and azacitidine for AML ineligible for standard induction
Combination therapies with azacitidine for MDS
Combination therapies with azacitidine for MDS
SLS009, a CDK9 inhibitor, with azacitidine and venetoclax for R/R AML after prior venetoclax therapy
SLS009, a CDK9 inhibitor, with azacitidine and venetoclax for R/R AML after prior venetoclax therapy
OMNIVERSE: safety and tolerability of oral azacitidine plus venetoclax in patients with AML
OMNIVERSE: safety and tolerability of oral azacitidine plus venetoclax in patients with AML
Front-line treatment options for HR-MDS: can we move past azacitidine?
Front-line treatment options for HR-MDS: can we move past azacitidine?
QUAZAR: Oral Azacitidine Maintenance in AML
QUAZAR: Oral Azacitidine Maintenance in AML
Gilteritinib plus azacitidine versus azacitidine monotherapy for newly diagnosed FLT3-mutated AML
Gilteritinib plus azacitidine versus azacitidine monotherapy for newly diagnosed FLT3-mutated AML
Venetoclax plus azacitidine for higher-risk MDS
Venetoclax plus azacitidine for higher-risk MDS
AML: Managing AEs With Venetoclax + Azacitidine
AML: Managing AEs With Venetoclax + Azacitidine
Immune checkpoint inhibitors for AML: mechanism, rationale & using azacitidine to boost response
Immune checkpoint inhibitors for AML: mechanism, rationale & using azacitidine to boost response
Venetoclax + azacitidine in unfit patients with AML
Venetoclax + azacitidine in unfit patients with AML
Evaluating long-term survival in patients with AML who discontinued azacitidine-venetoclax
Evaluating long-term survival in patients with AML who discontinued azacitidine-venetoclax
Rationale of OMNIVERSE: oral azacitidine + venetoclax in patients with R/R or newly diagnosed AML
Rationale of OMNIVERSE: oral azacitidine + venetoclax in patients with R/R or newly diagnosed AML
Long-term OS with oral azacitidine in patients with acute myeloid leukaemia in first remission a...
Long-term OS with oral azacitidine in patients with acute myeloid leukaemia in first remission a...